Patterns of autoantibody expression in multiple sclerosis identified through development of an autoantigen discovery technology
Authors:
- Europe B. DiCilloEurope B. DiCillo
- Evgueni KountikovEvgueni Kountikov
- Minghua ZhuMinghua Zhu
- Stefan LankerStefan Lanker
- Danielle E. HarlowDanielle E. Harlow
- Elizabeth R. PietteElizabeth R. Piette
- Weiguo ZhangWeiguo Zhang
- Brooke HaywardBrooke Hayward
- Joshua HeulerJoshua Heuler
- Julie KorichJulie Korich
- Jeffrey L. BennettJeffrey L. Bennett
- David PisetskyDavid Pisetsky
Open Access
- 31 December 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (5)
Abstract
Multiple sclerosis (MS) is a debilitating autoimmune disease of the CNS, which is characterized by demyelination and axonal injury and frequently preceded by a demyelinating event called clinically isolated syndrome (CIS). Despite the importance of B cells and autoantibodies in MS pathology, their target specificities remain largely unknown. For an agnostic and comprehensive evaluation of autoantibodies in MS, we developed and employed what we believe to be a novel autoantigen discovery technology, the Antigenome Platform. This Platform is a high-throughput assay comprising large-fragment (approximately 100 amino acids) cDNA libraries, phage display, serum antibody screening technology, and robust bioinformatics analysis pipelines. For autoantibody discovery, we assayed serum samples from CIS patients who received either placebo or treatment who were enrolled in the REFLEX clinical trial, which assessed the effects of IFN-β-1a (Rebif) clinical and MRI activity in patients with CIS. Serum autoantibodies from patients with CIS were significantly and reproducibly enriched for known and previously unreported protein targets; 166 targets were selected by over 10% of patients’ sera. Further, 10 autoantibody biomarkers associated with disease activity and 17 associated with patient response to IFN-β-1a therapy. These findings indicate widespread autoantibody production in MS and provide biomarkers for continued study and prediction of disease progression.Keywords
Funding Information
- U.S. Department of War (W81XWH1910639)
- EMD Serono (Collaborative Research Grant)
- Norges Idrettshøgskole (NEI R01EY022936)
- Norges Idrettshøgskole (R21EY032399)
- Guthy-Jackson Charitable Foundation (Identifying the microbial)
- Guthy-Jackson Charitable Foundation (self-antigenomes of NMO/NMOSD)
This publication has 87 references indexed in Scilit:
- Long time interval between multiple sclerosis onset and occurrence of primary Sjogren's syndrome in a woman treated with interferon-betaActa Neurologica Scandinavica, 2005
- Interferon beta-1b treatment does not induce autoantibodiesNeurology, 2005
- Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1bJournal of Neurology, 2004
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome.Journal of Neuroimmunology, 2002
- Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosisMultiple Sclerosis Journal, 2000
- Increased Risk of Autoimmune Thyroid Disease in Hepatitis C vs Hepatitis B Before, During, and After Discontinuing Interferon TherapyArchives of internal medicine (1960), 1998
- Exacerbation of Thyroid Autoimmunity by Interferon .ALPHA. Treatment in Patients with Chronic Viral Hepatitis: Our Studies and Review of the Literature.Endocrine Journal, 1994
- Continuous and discontinuous protein antigenic determinantsNature, 1986
- Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion SurfaceScience, 1985